324 related articles for article (PubMed ID: 23666970)
1. DNA methylation signatures identify biologically distinct thyroid cancer subtypes.
Rodríguez-Rodero S; Fernández AF; Fernández-Morera JL; Castro-Santos P; Bayon GF; Ferrero C; Urdinguio RG; Gonzalez-Marquez R; Suarez C; Fernández-Vega I; Fresno Forcelledo MF; Martínez-Camblor P; Mancikova V; Castelblanco E; Perez M; Marrón PI; Mendiola M; Hardisson D; Santisteban P; Riesco-Eizaguirre G; Matías-Guiu X; Carnero A; Robledo M; Delgado-Álvarez E; Menéndez-Torre E; Fraga MF
J Clin Endocrinol Metab; 2013 Jul; 98(7):2811-21. PubMed ID: 23666970
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis.
Ferraro A; Schepis F; Leone V; Federico A; Borbone E; Pallante P; Berlingieri MT; Chiappetta G; Monaco M; Palmieri D; Chiariotti L; Santoro M; Fusco A
J Clin Endocrinol Metab; 2013 Jul; 98(7):2834-43. PubMed ID: 23666966
[TBL] [Abstract][Full Text] [Related]
4. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
5. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis.
Aldred MA; Ginn-Pease ME; Morrison CD; Popkie AP; Gimm O; Hoang-Vu C; Krause U; Dralle H; Jhiang SM; Plass C; Eng C
Cancer Res; 2003 Jun; 63(11):2864-71. PubMed ID: 12782592
[TBL] [Abstract][Full Text] [Related]
8. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
9. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
10. Differential (Ha-, K- and N-) ras p21 expression in benign and malignant human thyroid tumors: an immunohistochemical study.
Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Nakamura S; Hashimoto T
Anticancer Res; 1995; 15(3):755-9. PubMed ID: 7645954
[TBL] [Abstract][Full Text] [Related]
11. Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers.
Ogasawara S; Maesawa C; Yamamoto M; Akiyama Y; Wada K; Fujisawa K; Higuchi T; Tomisawa Y; Sato N; Endo S; Saito K; Masuda T
Oncogene; 2004 Feb; 23(5):1117-24. PubMed ID: 14743202
[TBL] [Abstract][Full Text] [Related]
12. Methylation status of genes in papillary thyroid carcinoma.
Smith JA; Fan CY; Zou C; Bodenner D; Kokoska MS
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1006-11. PubMed ID: 17938324
[TBL] [Abstract][Full Text] [Related]
13. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma.
Graff JR; Greenberg VE; Herman JG; Westra WH; Boghaert ER; Ain KB; Saji M; Zeiger MA; Zimmer SG; Baylin SB
Cancer Res; 1998 May; 58(10):2063-6. PubMed ID: 9605742
[TBL] [Abstract][Full Text] [Related]
14. [The significance of p63 expression in thyroid neoplasm].
Qian M; Wang J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Oct; 22(19):888-90, 893. PubMed ID: 19160863
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
[TBL] [Abstract][Full Text] [Related]
17. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors in differentiated thyroid gland carcinoma].
Fonseca E; Soares P; Rossi S; Sobrinho-Simões M
Pathologe; 1997 Jul; 18(4):275-85. PubMed ID: 9380603
[TBL] [Abstract][Full Text] [Related]
19. ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a.
Qiang W; Zhao Y; Yang Q; Liu W; Guan H; Lv S; Ji M; Shi B; Hou P
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1163-72. PubMed ID: 24684457
[TBL] [Abstract][Full Text] [Related]
20. Raf-1 kinase inhibitory protein expression in thyroid carcinomas.
Kim HS; Kim GY; Lim SJ; Kim YW
Endocr Pathol; 2010 Dec; 21(4):253-7. PubMed ID: 20734161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]